Rewired ERK-JNK signaling pathways in melanoma

被引:248
作者
Lopez-Bergami, Pablo
Huang, Conway
Goydos, James S.
Yip, Dana
Bar-Eli, Menashe
Herlyn, Meenhard
Smalley, Keiran S. M.
Mahale, Alka
Eroshkin, Alexey
Aaronson, Stuart
Ronai, Ze'ev [1 ]
机构
[1] Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA
[2] CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA
[3] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA
[4] Univ Med & Dent New Jersey, Robert Wood Johson Med Sch, Div Surg Oncol, Piscataway, NJ 08854 USA
[5] MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
[6] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/j.ccr.2007.03.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Constitutive activation of MEK-ERK signaling is often found in melanomas. Here, we identify a mechanism that links ERK with JNK signaling in human melanoma. Constitutively active ERK increases c-Jun transcription and stability, which are mediated by CREB and GSK3, respectively. Subsequently, c-Jun increases transcription of target genes, including RACK1, an adaptor protein that enables PKC to phosphorylate and enhance JNK activity, enforcing a feed-forward mechanism of the JNK-Jun pathway. Activated c-Jun is also responsible for elevated cyclin 131 expression, which is frequently overexpressed in human melanoma. Our data reveal that, in human melanoma, the rewired ERK signaling pathway upregulates JNK and activates the c-Jun oncogene and its downstream targets, including RACK1 and cyclin D1.
引用
收藏
页码:447 / 460
页数:14
相关论文
共 60 条
[1]   A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos [J].
Ahn, S ;
Olive, M ;
Aggarwal, S ;
Krylov, D ;
Ginty, DD ;
Vinson, C .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (02) :967-977
[2]  
Alsina J, 2003, CLIN CANCER RES, V9, P6419
[3]   THE JUN PROTO-ONCOGENE IS POSITIVELY AUTOREGULATED BY ITS PRODUCT, JUN/AP-1 [J].
ANGEL, P ;
HATTORI, K ;
SMEAL, T ;
KARIN, M .
CELL, 1988, 55 (05) :875-885
[4]   The specificities of protein kinase inhibitors: an update [J].
Bain, J ;
McLauchlan, H ;
Elliott, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2003, 371 :199-204
[5]   MOLECULAR PATHOLOGY OF THE CELL-CYCLE IN HUMAN CANCER-CELLS [J].
BARTEK, J ;
STASKOVA, Z ;
DRAETTA, G ;
LUKAS, J .
STEM CELLS, 1993, 11 :51-58
[6]   The retinoblastoma protein pathway and the restriction point [J].
Bartek, J ;
Bartkova, J ;
Lukas, J .
CURRENT OPINION IN CELL BIOLOGY, 1996, 8 (06) :805-814
[7]   RACK1 is up-regulated in angiogenesis and human carcinomas [J].
Berns, H ;
Humar, R ;
Hengerer, B ;
Kiefer, FN ;
Battegay, EJ .
FASEB JOURNAL, 2000, 14 (15) :2549-2558
[8]   Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity [J].
Bhoumik, A ;
Jones, N ;
Ronai, Z .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (12) :4222-4227
[9]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[10]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105